Skip to main content

Advertisement

Table 2 Patient and tumor characteristics, overall and by histologic categories

From: Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas

  All patients Leiomyo-sarcomas Undifferentiated pleomorphic sarcoma Liposarcomas Vascular sarcomas Fibroblastic/myofibroblastic sarcomas Nerve sheath sarcomas Rhabdomyo-sarcomas Synovial sarcomas Others/NOS
N 4274 922 652 554 357 227 106 98 49 1309
Sex (n, %)
 Male 2103 (49.2) 307 (33.3) 390 (59.8) 329 (59.4) 195 (54.6) 122 (53.7) 64 (60.4) 43 (43.9) 28 (57.1) 625 (47.8)
 Female 2171 (50.8) 615 (66.7) 262 (40.2) 225 (40.6) 162 (45.4) 105 (46.3) 42 (39.6) 55 (56.1) 21 (42.9) 684 (52.2)
Race
 White 3729 (87.3) 783 (84.9) 576 (88.3) 499 (90.1) 309 (86.6) 203 (89.4) 96 (90.6) 82 (83.7) 43 (87.8) 1138 (86.9)
 Black 337 (7.9) 106 (11.5) 46 (7.1) 23 (4.2) 21 (5.9) 106 (8.1)
 Other 197 (4.6) 31 (3.4) 26 (4.0) 32 (5.8) 25 (7.0) 63 (4.8)
Age at advanced diagnosis
 Mean (SD) 77.8 (7.3) 76.8 (7.2) 79.4 (7.2) 77.5 (7.1) 78.2 (7.5) 77.8 (7.1) 77.7 (7.6) 76.8 (7.3) 74.1 (6.5) 78.0 (7.4)
 Median 77.4 76.1 79.7 76.6 77.9 77.8 77.3 76.6 73.5 77.5
 Min, Max 65.0, 104.1 65.0, 102.9 65.1, 99.3 65.1, 96.8 65.6, 101.8 65.7, 97.4 65.5, 95.9 65.3, 95.3 65.7, 91.0 65.1, 104.1
Pre-index date Charlson Comorbidity Index (CCI) scorea
 Mean (SD) 2.8 (2.3) 2.5 (2.2) 2.8 (2.4) 2.8 (2.3) 2.9 (2.7) 2.8 (2.2) 2.8 (2.3) 2.6 (2.1) 3.0 (2.3) 2.8 (2.4)
 Median 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0
 Min, Max 0.0, 15.0 0.0, 14.0 0.0, 15.0 0.0, 12.0 0.0, 12.0 0.0, 11.0 0.0, 10.0 0.0, 9.0 0.0, 8.0 0.0, 15.0
Stage of disease at initial diagnosis of STS (n, %)
 Localized 1731 (40.5) 345 (37.4) 379 (58.1) 260 (46.9) 150 (42.0) 121 (53.3) 36 (34.0) 25 (25.5) 18 (36.7) 397 (30.3)
 Regional—direct extension only 938 (22.0) 200 (21.7) 135 (20.7) 177 (32.0) 62 (17.4) 59 (26.0) 32 (30.2) 14 (14.3) 11 (22.5) 248 (19.0)
 Regional—lymph nodes involved only 29 (0.7) 0 (0.0)
 Regional—direct extension and lymph nodes 37 (0.9) 0 (0.0)
 Distant 1539 (36.0) 363 (39.4) 133 (20.4) 114 (20.6) 138 (38.7) 45 (19.8) 36 (34.0) 53 (54.1) 20 (40.8) 637 (48.7)
Grade of cancer at time of initial diagnosis of STS (n, %)
 Well or moderately differentiated (grade 1 or 2) 646 (15.1) 152 (16.5) 36 (5.5) 239 (43.1) 40 (11.2) 50 (22.0) 116 (8.9)
 Poorly differentiated (grade 3) 908 (21.2) 192 (20.8) 151 (23.2) 101 (18.2) 81 (22.7) 35 (15.4) 16 (32.7) 294 (22.5)
 Undifferentiated (grade 4) 1310 (30.7) 250 (27.1) 228 (35.0) 129 (23.3) 61 (17.1) 63 (27.8) 28 (26.4) 34 (34.7) 510 (39.0)
 Unknown 1410 (33.0) 328 (35.6) 237 (36.4) 85 (15.3) 175 (49.0) 79 (34.8) 54 (50.9) 39 (39.8) 24 (49.0) 389 (29.7)
Total follow-up time (years)b
 Mean (SD) 1.7 (2.4) 1.8 (2.2) 2.0 (2.8) 2.6 (2.8) 1.1 (1.7) 2.5 (2.7) 1.4 (2.1) 0.8 (1.5) 1.4 (1.8) 1.3 (2.0)
 Median 0.7 1.0 0.8 1.5 0.5 1.6 0.5 0.3 0.6 0.5
 Min, Max 0.0, 12.8 0.0, 12.2 0.0, 12.3 0.0, 12.3 0.0, 12.5 0.0, 12.5 0.0, 9.9 0.0, 9.8 0.0, 8.8 0.0, 12.8
  1. ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification, Max maximum, Min minimum, NOS not otherwise specified, SD standard deviation, STS soft-tissue sarcoma
  2. aBecause the objective of the CCI score was to evaluate underlying comorbidity burden independent of STS, ICD-9-CM diagnosis codes for cancer were excluded from the CCI calculation for this study
  3. bFollow-up time calculated as the number of months between the study index date (first diagnosis of advanced STS) and the earliest of death, loss of eligibility, or end of the Medicare database (December 31, 2013)